These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 22589042)

  • 1. Impact of safety monitoring on error probabilities of binary efficacy outcome analyses in large phase III group sequential trials.
    Weng Y; Zhao W; Palesch Y
    Pharm Stat; 2012; 11(4):310-7. PubMed ID: 22589042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the impact of safety monitoring on the efficacy analysis in large Phase III group sequential trials with non-trivial safety event rate.
    Weng Y; Palesch YY; DeSantis SM; Zhao W
    J Biopharm Stat; 2016; 26(4):672-85. PubMed ID: 26010228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Group-sequential methods for adaptive seamless phase II/III clinical trials.
    Stallard N
    J Biopharm Stat; 2011 Jul; 21(4):787-801. PubMed ID: 21516569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Designing multi-arm multi-stage clinical trials using a risk-benefit criterion for treatment selection.
    Jaki T; Hampson LV
    Stat Med; 2016 Feb; 35(4):522-33. PubMed ID: 26456537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adaptive seamless designs with interim treatment selection: a case study in oncology.
    Carreras M; Gutjahr G; Brannath W
    Stat Med; 2015 Apr; 34(8):1317-33. PubMed ID: 25640198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interim futility analysis with intermediate endpoints.
    Goldman B; LeBlanc M; Crowley J
    Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A decision rule for sequential monitoring of clinical trials with a primary and supportive outcome.
    Zhao Y; Grambsch PM; Neaton JD
    Clin Trials; 2007; 4(2):140-53. PubMed ID: 17456513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistical aspects of the TNK-S2B trial of tenecteplase versus alteplase in acute ischemic stroke: an efficient, dose-adaptive, seamless phase II/III design.
    Levin B; Thompson JL; Chakraborty B; Levy G; MacArthur R; Haley EC
    Clin Trials; 2011 Aug; 8(4):398-407. PubMed ID: 21737464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adaptive group-sequential design with population enrichment in phase 3 randomized controlled trials with two binary co-primary endpoints.
    Sinha AK; Moye L; Piller LB; Yamal JM; Barcenas CH; Lin J; Davis BR
    Stat Med; 2019 Sep; 38(21):3985-3996. PubMed ID: 31184783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A two-stage group-sequential design for delayed treatment responses with the possibility of trial restart.
    Schüürhuis S; Konietschke F; Kunz CU
    Stat Med; 2024 May; 43(12):2368-2388. PubMed ID: 38564226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials.
    Claggett B; Pocock S; Wei LJ; Pfeffer MA; McMurray JJV; Solomon SD
    Circulation; 2018 Aug; 138(6):570-577. PubMed ID: 29588314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of clinical trials with failure-time endpoints and interim analyses: An update after fifteen years.
    He P; Lai TL; Su Z
    Contemp Clin Trials; 2015 Nov; 45(Pt A):103-12. PubMed ID: 26031459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flexible selection of a single treatment incorporating short-term endpoint information in a phase II/III clinical trial.
    Stallard N; Kunz CU; Todd S; Parsons N; Friede T
    Stat Med; 2015 Oct; 34(23):3104-15. PubMed ID: 26112909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of type I error rate associated with dose-group switching in a longitudinal Alzheimer trial.
    Habteab Ghebretinsae A; Molenberghs G; Dmitrienko A; Offen W; Sethuraman G
    J Biopharm Stat; 2014; 24(3):660-84. PubMed ID: 24697817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A modified varying-stage adaptive phase II/III clinical trial design.
    Dong G; Vandemeulebroecke M
    Pharm Stat; 2016 Jul; 15(4):368-78. PubMed ID: 27264007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Supplementary analysis of probabilities at the termination of a group sequential phase II trial.
    Liu A; Wu C; Yu KF; Gehan E
    Stat Med; 2005 Apr; 24(7):1009-27. PubMed ID: 15565737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential design of phase II-III cancer trials.
    Lai TL; Lavori PW; Shih MC
    Stat Med; 2012 Aug; 31(18):1944-60. PubMed ID: 22422502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sample size planning for phase II trials based on success probabilities for phase III.
    Götte H; Schüler A; Kirchner M; Kieser M
    Pharm Stat; 2015; 14(6):515-24. PubMed ID: 26412484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An introduction to the use of interim data analyses in clinical trials.
    Lewis RJ
    Ann Emerg Med; 1993 Sep; 22(9):1463-9. PubMed ID: 8363121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An adaptive design to bridge the gap between Phase 2b/3 microbicide effectiveness trials and evidence required for licensure.
    Taylor DJ; Grobler A; Abdool Karim SS
    Clin Trials; 2012 Aug; 9(4):377-84. PubMed ID: 22610168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.